https://www.selleckchem.com/products/k03861.html
Median (IQR) eGFR at baseline and 1year were 71.9mL/min/1.73m (56.5-82) and 63.0mL/min/1.73m (54.0-78.2); the difference was -5.3 (p=0.12). Two Clavien-Dindo type-I complications, one type-II complication, and one type-III complication were experienced in this cohort. Median radiographic follow-up was 376.5days with 2 tumors (2.4% of RCC/oncocytic neoplasms) having recurred to date. MWA is a safe and efficacious treatment option for small renal masses with minimal adverse events and low rates of recurrence in this cohort of 101 patients.
Like
Comment
Share
